Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cancer Research|May 16, 2018
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical ModelYan Liu, Yuyang Li, Shengwu Liu, et al.
Cancer Immunology Research|August 9, 2018
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung CancerDennis O Adeegbe, Shengwu Liu, Maureen M Hattersley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung CancerElena Ivanova, Mari Kuraguchi, Man Xu, et al.
Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Cancer Research|August 12, 2021
Targeting <i>HER2</i> Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor MobocertinibHan Han, Shuai Li, Ting Chen, et al.
Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.
Cancer Discovery|April 15, 2017
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung CancerDennis O Adeegbe, Yan Liu, Patrick H Lizotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2018
Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS<sup>G12C</sup>-Driven Mouse Model of Lung CancerShuai Li, Shengwu Liu, Jiehui Deng, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activityJason J Kwon, Julien Dilly, Shengwu Liu, et al.
Nature Medicine|August 15, 2017
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4Xiangpeng Dai, Wenjian Gan, Xiaoning Li, et al.
Pageof 4